Moreover, after promising results in a randomized phase II trial [17], iniparib (the actual anti-PARP activity of which remains discussed) in combination with chemotherapy failed to demonstrate any survival advantage in triple-negative metastatic breast cancer [18], a subset of tumors sharing some similarities with BRCA-mutated breast cancer. The gene discussed is PARP1; the disease is breast cancer.